Skip to main content
Fig. 4 | Allergy, Asthma & Clinical Immunology

Fig. 4

From: Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Fig. 4

Changes from baseline in total and individual item scores of the RQLQ after 2 weeks of randomized therapy. a Phase 2 trial (based on modified all-treated set) and b Phase 3 trial based on modified ITT (intent-to-treat) set. All data are expressed as mean (95% CI). RQLQ rhinoconjunctivitis quality-of-life questionnaire. *p < 0.05 for change from baseline with setipiprant vs. placebo; †p < 0.05 for change from baseline with cetirizine vs. placebo

Back to article page